Oncology Xagena

Xagena Mappa
Xagena Newsletter

Localized low-grade prostate cancer: no aggressive treatment

A study does not support aggressive treatment for localized, low-grade prostate cancer, indicating a small risk of progression of this grade of cancer.

A recent study suggested an increasing prostate cancer death rate for men who are alive more than 15 years following diagnosis. The appropriate therapy for men with clinically localized prostate cancer has been uncertain.

Peter C. Albertsen, of the University of Connecticut Health Center, Farmington, and colleagues conducted a study to determine whether prostate cancer death rates declined, remained constant, or increased after 15 years.

Researchers used data from the Connecticut Tumor Registry, supplemented by hospital record and histology review of 767 men aged 55 to 74 years with clinically localized prostate cancer diagnosed between January 1, 1971, and December 31, 1984.
Patients were treated with either observation or immediate or delayed androgen withdrawal therapy, with an observation period of 24 years being the norm.

Researchers found: " Extended follow-up of our competing risk analysis suggests that prostate cancer progression rates do not increase after 15 years of follow-up. Men with low-grade prostate cancer have only a small risk of prostate cancer progression even after 20 years of management by observation or androgen withdrawal therapy alone. These results do not support aggressive treatment of localized low-grade prostate cancer. Men with poorly differentiated disease ( Gleason scores of 7 and 8-10 ) have a high risk of death from prostate cancer; only 3 men were alive after 20 years. Men with moderate-grade disease ( Gleason scores of 5-6 ) have an intermediate cumulative risk of prostate cancer progression after 20 years of follow-up."

" Our data provide what are likely overestimates of prostate cancer progression when men are treated by observation or androgen withdrawal therapy alone. Only through randomized controlled trials designed to measure the efficacy of screening and treatment for prostate cancer can we answer questions concerning which patients may truly benefit," the authors conclude.

Source: Journal of American Medical Association, 2005